natgillin/translations-raw huggingface dataset:
Behandlingsopstartspakning – indeholder to fyldte penne hver med 14 doser.
Treatment Initiation pack - Contains two pre-filled pens each with 14 doses.
Behandlingsopstartspakningen indeholder en grøn pen Lyxumia 10 mikrogram, og en lilla pen Lyxumia 20 mikrogram.
The treatment initiation pack contains one green pen for Lyxumia 10 micrograms and one purple pen for Lyxumia 20 micrograms.
Behandlingsperiode 1
Treatment Period 1
Behandlingsperiode efter operation 2
Post-surgery treatment period 2
Behandlingsperioden var 12 måneder forudgået af en 4-9- ugers screeningsperiode, hvor der blev givet tilskud af calcium og D-vitamin i mindst 2 uger.
The study treatment period was 12 months preceded by a 4- to 9-week screening period during which vitamin D and elemental calcium supplements were taken for at least 2 weeks.
Behandlingsplanen bestod af administration af genetisk modificerede donor-T-lymfocytter (fra 1 x 106 til 1 x 107 celler/kg kropsvægt).
Treatment plan consisted of the administration of genetically modified donor’s T lymphocytes (ranging from 1 x 106 to 1 x 107 cells/kg body weight).
Behandlingsplanen bør baseres på individuel veterinær diagnose samt den lokale epidemiologiske situation.:
The treatment schedule should be based on individual veterinary diagnosis and on the local epidemiological situation.
Behandlingsplanen bør baseres på individuel veterinær diagnose samt den lokale epidemiologiske situation:
The treatment schedule should be based on individual veterinary diagnosis and on the local epidemiological situation.
Behandlingsplanen for patienter, der udvikler ONJ, bør udfærdiges i tæt samarbejde mellem den behandlende læge og en tandlæge eller en kæbekirurg med erfaring i ONJ.
The management plan for the patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ.
Behandlingsprogram
Table 1.
Behandlingsprogram
Treatment regimen
Behandlingsprogram/- varighed
Regimen/Duration
Behandlingsprogram/-varighed
Regimen/Duration
Behandlingsprogrammet består af to sprøjter.
The treatment regimen consists of two syringes.
Behandlingsprogrammet med en enkelt tablet (single tablet regimen – STR) Eviplera er blevet undersøgt hos virologisk supprimerede patienter, som skiftede fra et program indeholdende en ritonavir-boosted proteasehæmmer (fase III-studie GS-US-264-0106) eller fra efavirenz/emtricitabin/tenofovirdisoproxilfumarat (fase IIb-studie GS-US-264-0111).
The single-tablet regimen (STR), Eviplera, has been studied in virologically suppressed patients who switched from a regimen containing a ritonavir-boosted protease inhibitor (Phase III study GS-US-264-0106) or from efavirenz/emtricitabine/tenofovir disoproxil fumarate (Phase IIb study GS-US-264-0111).
Behandlingsprøve af stamceller udtages
Treatment sample of stem cells collected
Behandlingsregime
Treatment regimen
Behandlingsregime uge 0 til 16
Treatment regimen week 0 to 16
Behandlingsregimen
Regimen
Behandlingsregimen Antal patienter
Treatment regimen Number of patients
Behandlingsregimerne for flere proteasehæmmere, som er subjekt for denne interaktion, kræver samtidig administration af lavdosis ritonavir (“boosting”) for at øge plasmakoncentrationerne og optimere den antivirale virkning.
Treatment paradigms for several protease inhibitors, which are subject to this interaction, require the co-administration of low-dose ritonavir (‘boosting’) in order to enhance plasma levels and optimise antiviral efficacy.
Behandlingsregimet med aprepitant bestod af aprepitant 125 mg på dag 1 og 80 mg/dag på dag 2 og 3 i kombination med ondansetron 32 mg IV på dag 1 og dexamethason 12 mg på dag 1 og 8 mg dagligt på dag 2-4.
The aprepitant regimen consisted of aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 and 3 in combination with ondansetron 32 mg IV on Day 1 and dexamethasone 12 mg on Day 1 and 8 mg daily on Days 2 through 4.
Behandlingsrelaterde bivirkninger af sværhedsgrad 3 eller 4 var dog hyppigere hos patienter ≥ 60 år sammenlignet med yngre patienter.
However, grade 3 or 4 treatment-related adverse reactions were more frequent in patients ≥60 years of age compared to younger patients.
Behandlingsrelaterede alvorlige bivirkninger blev set hos 23,7% af de patienter, som fik sunitinib, og hos 6,9% af de patienter, som fik IFN-α- behandling.
Treatment-related serious adverse events (TRSAEs) were reported in 23.7% of patients receiving sunitinib and in 6.9% of patients receiving IFN-α.
Behandlingsrelaterede aminosyresubstitutioner i den samlede analyse af regimer med Exviera og ombitasvir/paritaprevir/ritonavir med og uden ribavirin i kliniske fase 2b- og fase 3- studier (N = 2.510)
Treatment-emergent amino acid substitutions in the pooled analysis of Exviera and ombitasvir/paritaprevir/ritonavir, with and without RBV regimens in Phase 2b and Phase 3 clinical trials (N=2510)
Behandlingsrelaterede bivirkninger af sværhedsgrad 3 eller 4 var dog hyppigere hos patienter  60 år sammenlignet med yngre patienter.
However, grade 3 or 4 treatment-related adverse reactions were more frequent in patients ≥60 years of age compared to younger patients.
Behandlingsrelaterede bivirkninger rapporteret i ovariecancer kliniske undersøg- elser (50 mg/m2 hver 4. uge) (Caelyx-behandlede patienter) efter sværhedsgrad, systemorganklasser i henhold til MedDRA-databasen og standardterminologi
Treatment related undesirable effects reported in ovarian cancer clinical trials (50 mg/m2 every 4 weeks) (Caelyx-treated patients) by severity, MedDRA system organ class and preferred term
Behandlingsrelaterede bivirkninger, der er rapporteret ved kliniske undersøgelser af myelomatose (Caelyx 30 mg/m2 i kombination med bortezomib hver 3. uge) efter sværhedsgrad, systemorganklasser i henhold til MedDRA-databasen og foretrukken term
Treatment related undesirable effects reported in multiple myeloma clinical trial (Caelyx 30 mg/m2 in combination with bortezomib every 3 weeks) by severity, MedDRA system organ class and preferred term
Behandlingsrelaterede dødsfald forekom hos 1,2 % af patienterne i Perjeta-gruppen og hos 1,5 % af patienterne i placebo-gruppen og skyldtes hovedsageligt febril neutropeni og/eller infektion.
Treatment-related deaths occurred in 1.2% of patients in the Perjeta-treated group and 1.5% of patients in the placebo-treated group and were mainly due to febrile neutropenia and/or infection.
Behandlingsrelaterede klinisk-patologiske ændringer var begrænset til stigning i gennemsnitlig serumcholesterol og et fald i gennemsnitlig leukocyttal, alle middelværdier forblev dog indenfor det laboratoriske referenceområde.
Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range.
Behandlingsrelaterede kliniske tegn var hovedsagelig relateret til sedation, nedsat fødeindtagelse og sekundære forandringer i legemsvægt, vægtøgning og organvægt.
Treatment- related clinical signs were mainly related to sedation, reduced food consumption and secondary changes in body weight, body weight gain and organ weights.
Behandlingsrelaterede substitutioner blev detekteret i targets for begge HCV-lægemidler hos 23/37 (62%) forsøgspersoner med genotype 1a, 1/8 (13%) forsøgspersoner med genotype 1b og 2/5 (40%) forsøgspersoner med genotype 4.
Treatment-emergent substitutions were detected in both HCV drug targets in 23/37 (62 %) genotype 1a, 1/8 (13 %) genotype 1b and 2/5 (40 %) genotype 4subjects.
Behandlingsrelaterede, klinisk patologiske ændringer var begrænset til stigning i gennemsnitlig serumcholesterol og et fald i gennemsnitlig leukocyttal, alle middelværdier forblev dog indenfor det laboratoriske referenceområde.
Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range.
Behandlingsrelateret mortalitet (BRM) og transplantationsrelateret mortalitet (TRM): Der er rapporteret BRM-værdier fra 2,5 % til 29 %.
Regimen Related Mortality (RRM) and Transplant Related Mortality TRM : RRM values ranging from 2.5% to 29% have been reported.
Behandlingsrelateret mortalitet (BRM) og transplantationsrelateret mortalitet (TRM): Der er rapporteret lave værdier, hvilket bekræfter sikkerheden ved konditioneringer med thiotepa til allogen HPCT hos voksne med hæmatologiske sygdomme.
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): low values have been reported, confirming the safety of the conditioning treatments including thiotepa for allogeneic HPCT in adults patients with haematological diseases.
Behandlingsrelateret mortalitet (BRM) og transplantationsrelateret mortalitet (TRM): Der er rapporteret lave værdier, hvilket bekræfter sikkerheden ved konditioneringerne med thiotepa til allogen HPCT hos voksne med hæmatologiske sygdomme.
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): low values have been reported, confirming the safety of the conditioning treatments including thiotepa for allogeneic HPCT in adults patients with haematological diseases.
Behandlingsrelateret resistens hos tidligere ubehandlede patienter, svigtende behandling
Treatment emergent resistance in previously untreated patients failing therapy
Behandlingsrespons
18.9 [15.8, 22.2]
Behandlingsrespons
Treatment outcome
Behandlingsrespons* i uge 48 (poolede RESIST-1 og RESIST-2-studie med behandlingserfarne patienter)
Treatment response* at week 48 (pooled studies RESIST-1 and RESIST-2 in treatment- experienced patients)
Behandlingsresponset med tenofovirdisoproxilfumarat var sammenligneligt hos nukleos(t)id-naive (n = 20) og nukleos(t)idbehandlede (n = 32) patienter, herunder lamivudin-resistente patienter (n = 6).
Response to treatment with tenofovir disoproxil fumarate was comparable in nucleos(t)ide-naïve (n = 20) and nucleos(t)ide-experienced (n = 32) patients, including lamivudine- resistant patients (n = 6).
Behandlingsresulta t
(study HPC2002)
Behandlingsresultat Med RBV Uden RBV
Treatment outcome With RBV Without RBV
Behandlingsresultaterne for studie GS-US-311-1089 til og med uge 48 vises i tabel 6.
Treatment outcomes of study GS-US-311-1089 through 48 weeks are presented in Table 6.
Behandlingssammenligning: Macitentan 10 mg vs. placebo
Treatment Comparison: Macitentan 10 mg vs Placebo
Behandlingsserie 1
Cycle 1
Behandlingsserie 2 - 6
Cycles 2-6
Behandlingsserie 2 til 6
Cycles 2 to 6
Behandlingsserie 2-6
Cycle 2-6
Behandlingsserierne for alle kræfttyper vil sædvanligvis blive gentaget hver tredje uge.
This pattern of treatments will normally be repeated every three weeks, for all cancers.
Behandlingsskema
Schedule
Behandlingsskema
Treatment schedule:
Behandlingsskemaet skal baseres på dyrlægens diagnose og på smittestatus i det pågældende område.
The treatment schedule should be based on veterinary diagnosis and on the local epidemiological situation.
Behandlingsskift
Treatment switching
Behandlingsskift (primær forebyggelse af VTE ved ortopædkirurgi)
Switching (pVTEp orthopaedic surgery)
Behandlingsskift fra Aptivus kapsler til oral opløsning
Switching from Aptivus capsules to the oral solution
Behandlingsskift fra Aptivus oral opløsning til kapsler
Switching from Aptivus oral solution to the capsules
Behandlingsskift fra SSRI/SNRI-antidepressiva til agomelatin
Switching therapy from SSRI/SNRI antidepressant to agomelatine
Behandlingsstart (de første 4 uger)
Start of the treatment (the first 4 weeks)
Behandlingsstart ved graviditet (se pkt.
Initiation of treatment in pregnancy (see section 4.6).
Behandlingsstart/nye behandlingsforløb bør udsættes hos patienter med ikke-ophelede, åbne bløddelslæsioner i munden.
The start of treatment / new treatment course should be delayed in patients with unhealed open soft tissue lesions in the mouth.
Behandlingsstartpakke med 28 filmovertrukne tabletter til en 4-ugers behandlingsplan: 7 filmovertrukne Nemdatine 5 mg tabletter
Treatment initiation pack with 28 film-coated tablets for a 4 week treatment schedule: 7 film-coated tablets of Nemdatine 5 mg
Behandlingsstartpakken indeholder 4 pakninger, der hver indeholder 14 tabletter á 50 mg, 100 mg, 150 mg og 200 mg.
The treatment initiation pack contains 4 cartons, each carton with 14 tablets of 50 mg, 100 mg, 150 mg and 200 mg
Behandlingsstartpakken indeholder 56 filmovertrukne tabletter i 4 æsker: æsken mærket ‘Uge 1’ indeholder 14 tabletter á 50 mg, æsken mærket ‘Uge 2’ indeholder 14 tabletter á 100 mg, æsken mærket ‘Uge 3’ indeholder 14 tabletter á 150 mg, æsken mærket ‘Uge 4’ indeholder 14 tabletter á 200 mg.
The treatment initiation pack contains 56 film-coated tablets in 4 packages: the package marked ‘Week 1’contains 14 tablets of 50 mg, the package marked ‘Week 2’ contains 14 tablets of 100 mg, the package marked ‘Week 3’ contains 14 tablets of 150 mg, the package marked ‘Week 4’ contains 14 tablets of 200 mg .
Behandlingsstartpakning
Treatment initiation pack
Behandlingsstop
Discontinuation
Behandlingssuccesen blev defineret som en komplet, eller næsten komplet remission af mål- hæmangiomet, som blev evalueret af en blændet centraliseret uafhængig vurdering foretaget på fotografier ved uge 24, hvis der ikke var indtruffet en for tidlig afbrydelse af behandlingen.
Treatment success was defined as a complete or nearly complete resolution of the target haemangioma, which was evaluated by blinded centralized independent assessments made on photographs at Week 24, in the absence of premature treatment discontinuation.
Behandlingssvigt med CCR5-tropismevirus:
Failure with CCR5-tropic virus:
Behandlingssvigt med CXCR4-using virus:
Failure with CXCR4-using virus:
Behandlingssvigt, defineret som positive HBV- DNA- og HBsAg-resultater, blev ikke observeret i observationsperioden.
No treatment failure defined as positive HBV-DNA and HBsAg findings occurred during the entire observation period.
behandlingssvigt.
failure.
behandlingssvigt.
management in case of
behandlingssvigt.
Midazolam
Behandlingstid (min:sek)
Treatment time (min:sec)
Behandlingstid (sek)
Treatment time (sec)
Behandlingstiden er sædvanligvis 24 måneder.
Usual duration of treatment is 24 months.
Behandlingstiden kan forlænges hos nogle patienter.
In some patients, this treatment time may be prolonged.
Behandlingstiden var 24 uger (genotyper 2 og 3)og 48 uger (alle andre genotyper).
100 mcg/m2 sc once weekly and ribavirin 15 mg/kg/day for 24 weeks (genotypes 2 and 3) or 48 weeks (all other genotypes).
Behandlingsuge 4-responset var en bedre prediktor for SVR sammenlignet med responset på tidligere behandling og muliggjorde bestemmelse af forsøgspersonens on-treatment interferonfølsomhed.
The TW 4 response was a stronger predictor of SVR compared to response to previous treatment and allowed the determination of the subject's on-treatment interferon responsiveness.
Behandlingsuger n = antal evaluerbare patienter
Weeks of treatment n = number of patients evaluable
Behandlingsvarighed
Enoxaparin
Behandlingsvarighed - genbehandling
Duration of treatment – Retreatment
Behandlingsvarighed - naive patienter
Duration of treatment – Naïve patients
Behandlingsvarighed = 48 uger
Treatment duration = 48 weeks
Behandlingsvarighed for behandlingsnaive voksne og patienter, der har fået tilbagefald efter tidligere behandling (tidligere relapsers)
Duration of treatment – Treatment-naïve adults and prior treatment relapsers
Behandlingsvarighed hos børn og unge
Duration of treatment in children and adolescents
Behandlingsvarighed med ivacaftor (uger)
Duration of ivacaftor
Behandlingsvarighed med Vimpat
Duration of the treatment with Vimpat
Behandlingsvarighed ud over 24 uger skal baseres på lægens vurdering af patientens respons og vedligeholdelsesresponset på lang sigt.
The duration of treatment beyond 24 weeks should be subject to the physicians discretion based upon the patient response and maintenance response in the long-term.
Behandlingsvarighed var 12 måneder.
Treatment duration was 12-months.
Behandlingsvarighed var 6 måneder.
The treatment duration was 6 months.
Behandlingsvarighed – Genbehandling
Duration of treatment – Retreatment
Behandlingsvarighed – Naive patienter
Duration of treatment – Naïve patients
Behandlingsvarighed – to-stofsbehandling med Pegasys og ribavirin
Duration of treatment – dual therapy with Pegasys and ribavirin
Behandlingsvarighed – to-stofsbehandling med Pegasys og ribavirin
Duration of treatment –dual therapy with Pegasys and ribavirin
Behandlingsvarighed – to-stofsbehandling med Pegasys og ribavirin
Duration of treatment–dual therapy with Pegasys and ribavirin
Behandlingsvarighed, monitorering og dosisjusteringer
Treatment duration, monitoring and dose adjustments
Behandlingsvarigheden afhænger af infektions sværhedsgrad, infektionsstedet og patientens kliniske respons.
The duration of therapy should be guided by the severity, site of the infection, and the patient’s clinical response.
Behandlingsvarigheden afhænger af reaktionen på behandlingen.
Duration of treatment depends on the response to treatment.
Behandlingsvarigheden afhænger af risikoen for komplikationer og af de officielle anbefalinger.
The duration of treatment depends on the risk of complications and official recommendations.
Behandlingsvarigheden afhænger af sværhedsgraden af infektionen samt af hvor godt lægemidlet virker i kæledyret.
The duration of treatment depends on the severity of the infection and how well the medicine works in your pet.
Behandlingsvarigheden afhænger af sværhedsgraden samt af hvor godt lægemidlet virker i kæledyret.
The duration of treatment depends on the severity of the infection and how well the medicine works in your pet.
Behandlingsvarigheden er op til 1 år baseret på lægens vurdering for dig/barnet.
The duration of treatment is up to 1 year based on the doctor’s judgement for you, or the child you are caring for.
Behandlingsvarigheden i Fase 2- og 3-undersøgelser rangerede fra 6 uger til 64 uger.
The duration of treatment in Phase 2 and 3 studies ranged from 6 weeks to 64 weeks.
Behandlingsvarigheden med olaparib til patienter, som udviklede MDS/AML varierede fra < 6 måneder til > 2 år.
The duration of therapy with olaparib in patients who developed MDS/AML varied from < 6 months to > 2 years.
Behandlingsvarigheden med veterinærlægemidlet må ikke overskride 12 måneder, og dosis af veterinærlægemidlet må ikke overskride 0,2 ml/kg aktuel legemsvægt (1 mg/kg dirlotapid).
The duration of treatment with the veterinary medicinal product must not exceed 12 months and the dose of the veterinary medicinal product must not exceed a maximum of 0.2 ml/kg current bodyweight (1 mg/kg dirlotapide).
Behandlingsvarigheden var 6 måneder.
Treatment duration was 6 months.
Behandlingsvarigheden var fast i hvert studie og var ikke afhængig af forsøgspersonernes HCV-rna-niveauer (ingen responstilpasset algoritme).
Treatment duration was fixed in each trial and was not guided by subjects’ HCV RNA levels (no response guided algorithm).
Behandlingsvarigheden var fikseret i hvert studie, og den var ikke guidet af patienternes HCV-rna-niveauer (ingen responsguidet algoritme).
Treatment duration was fixed in each study and was not guided by subjects’ HCV RNA levels (no response guided algorithm).
Behandlingsvarigheden var fra 3 måneder op til 12 måneder, hvilket var bestemt af investigatoren baseret på patientens kliniske udtryk.
The treatment duration was from 3 months up to 12 months, determined by the investigator based on the patient’s clinical features.
Behandlingsvarigheden var mediant på 6 serier cabazitaxel.
Patients received a median duration of 6 cycles of cabazitaxel.
Behandlingsvarigheden var yderligere 6-12 måneder for patienter, der havde gennemført 6-12 måneders behandling for venøs tromboli afhængigt af investigators kliniske vurdering.
The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator.
Behandlingsvarigheden ved kronisk hepatitis C afhænger af viral genotype.
The duration of combination therapy with ribavirin for chronic hepatitis C depends on viral genotype.
Behandlingsvarigheden vil variere og afhænge af resultatet af dine blodprøver.
Your treatment may vary and will depend on the results of your regular blood tests.
Behandlingsvirkning
Treatment Outcome
behandlling med colchicin afbrydes
interruption of colchicine
Behold
keep
Behold dem kun, hvis Deres læge beder Dem om det.
Only keep them if your doctor tells you to.
Behold den ydre nålekapsel til at fjerne den brugte nål med.
The outer cap should be kept to remove the used needle.
Behold dette kort mindst 5 måneder efter sidste Trudexa-dosis, da bivirkninger kan forekomme i denne periode.
Keep this card with you for 5 months after the last Trudexa dose, since side effects may occur a long time after your last dose of Trudexa.
Behold dette kort under behandlingen og i 4 måneder efter endt behandling.
Keep this Card with you during treatment and for 4 months afterwards.
Behold enkeltdosisbeholderen og put resten tilbage i folieposen.
Put the others back in the foil wrapper.
Behold hætteglasadapteren eller nålen til overførsel på hætteglasset.
Keep the vial adapter or transfer needle attached to the vial.
Behold hætteglasset i den ydre pakning for at beskytte mod lys.
Keep the vial in the outer carton in order to protect from light.
Behold hætteglasset med injektionsvæske i den ydre emballage, så det beskyttes mod lys.
Keep the injection vial in the outer carton in order to protect from light.
Behold hætteglasset med injektionsvæske i den ydre emballage, så det beskyttes mod lys.
Keep the vial in the outer carton in order to protect from light.
Behold hætten på pennen for at beskytte mod lys.
Keep the pen cap to protect from light.
Behold hætten på pennen for at beskytte produktet mod lys.
Keep the cap on the pen in order to protect from light.
Behold hætten – du skal bruge den til at perforere membranen med.
Keep the cap – you need this to pierce the membrane.
Behold indlægssedlen og patientkortet under behandlingen og i 4 måneder efter den sidste dosis Zinbryta, da der kan opstå bivirkninger, også efter du har afsluttet behandlingen.
Keep the leaflet and Card with you during treatment and for 4 months after the last dose of Zinbryta, since side effects may occur even after you have stopped treatment.
Behold pennen i hånden, når du har taget hætten af.
Once you have taken the cap off, keep the pen in your hand.
BEHOLDER
BOTTLE
Beholder
Glass bottles
Beholder
Jar
Beholder
Syringe barrel
Beholder (10 ml, polystyren med polyethylen ”snaplåg” ) som indeholder 75 mg 13C-urinstof pulver til oral opløsning
Jar (10 ml volume, polystyrene with polyethylene snap cap) containing 75 mg 13C-urea powder for oral solution
Beholder (10 ml, polystyren med polyethylen ”snaplåg”), som indeholder 45 mg 13C-urinstof pulver til oral opløsning
Jar (10 ml volume, polystyrene with polyethylene snap cap) containing 45 mg 13C-urea powder for oral solution
Beholder (10 ml, polystyren med polyethylen ”snaplåg”), som indeholder 75 mg 13C-urinstof pulver til oral opløsning
Jar (10 ml volume, polystyrene with polyethylene snap cap) containing 75 mg 13C-urea powder for oral solution
Beholder (HDPE)
bottle (HDPE)
Beholder (HDPE)
Jar (HDPE)
Beholder (PET)
bottle (PET)
beholder (PP)
bottle (PP)
Beholder af HD-polyethylen (HDPE) med børnesikret låg af polypropylen.
High density polyethylene (HDPE) bottle with a child resistant polypropylene cap.
Beholder af HDPE (højdensitets polyethylen) med børnesikret låg, der indeholder 42, 60, 84, 90 eller 120 hårde kapsler.
High-density polyethylene (HDPE) bottle with child resistant closure containing 42, 60, 84, 90 or 120 hard capsules.
BEHOLDER ETIKET
BOTTLE LABEL
Beholder med hvidt skruelåg
White screw top container
Beholder med måleske (= 4,6 g pulver)
Jar with measuring spoon (= 4.6 g powder)
BEHOLDER MED SKRUELÅG
SCREW-CAP CONTAINER
BEHOLDER PAKNINGS MÆRKESEDDEL
(CONTAINER PACKAGE LABEL)
BEHOLDER TIL 14 OG 30 HÅRDE KAPSLER
BOTTLE FOR 14 AND 30 HARD CAPSULES
Beholder til 150 mg hårde kapsler – pakning med 200
Bottle immediate packaging for 150 mg hard capsules – pack of 200